UK gene therapy firm Orchard plans stock offer after GSK deal

LONDON (Reuters) - Britain's Orchard Therapeutics, which has already raised more than $140 million to fund its work in gene therapy, plans another private sale of shares following its acquisition of a portfolio of GlaxoSmithKline rare disease medicines.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news